Last reviewed 2026-04-22 · How we verify

BDL regimen

BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents.

BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB).

At a glance

Mechanism of action

BDL typically refers to a regimen combining Bedaquiline, Delamanid, and Linezolid, which are used together to treat drug-resistant tuberculosis. These agents work through different mechanisms: bedaquiline inhibits mycobacterial ATP synthase, delamanid is a prodrug that generates reactive nitrogen species, and linezolid inhibits bacterial protein synthesis. The combination approach is designed to overcome resistance mechanisms and improve treatment outcomes in difficult-to-treat TB cases.

Approved indications

• Drug-resistant tuberculosis (MDR-TB and XDR-TB)

Common side effects

• Peripheral neuropathy
• Hepatotoxicity
• QT prolongation
• Gastrointestinal disturbances
• Anemia

Key clinical trials

• Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
• The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• BDL regimen CI brief — competitive landscape report
• BDL regimen updates RSS · CI watch RSS
• Beijing Chest Hospital portfolio CI